Global Cardiac Biomarkers Testing Market

Cardiac Biomarkers Testing Comprehensive Study by Type (Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia-modified Albumin (IMA), Others), Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, Others), Product (Instruments, Chemiluminescence, Immunofluorescence, ELISA, Immunochromatography, Reagents and Kits), Location of Testing (Point of Care Testing, Laboratory Testing) Players and Region - Global Market Outlook to 2030

Cardiac Biomarkers Testing Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 10.1%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Cardiac Biomarkers Testing
Cardiac biomarkers are substances released into the blood when the heart is damaged or stressed. Cardiac biomarker testing is commonly used for and diagnosis and risk stratification in patients presenting with symptoms of AMI. These biomarkers are used to diagnose heart functioning, risk stratifications, and cardiac diseases in patients. A biomarker is a quantifiable and measurable biological parameter that includes an enzyme, hormones, and proteins, all associated with heart function, failure, or damage. Point of Care Cardiac Biomarker tests includes Troponin I, CK-MB, BNP, Pro-BNP, D-Dimer, and Myoglobin. CLIA-Waived and moderately complex platforms use small blood volumes of whole or venous samples. Time to results in minutes.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Billion)
CAGR10.1%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Cardiac Biomarkers Testing market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Abbott Laboratories (United States), Becton, Dickinson and Company (United States), BioMerieux SA (France), Bio-Rad Laboratories, Inc. (United States), Danaher Corporation (United States), Roche Holding AG (Switzerland), Siemens AG (Germany) and Thermo Fisher Scientific, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are PerkinElmer Inc. (United kingdom) and Tosoh Corporation (Japan).

Segmentation Overview
AMA Research has segmented the market of Global Cardiac Biomarkers Testing market by Type (Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia-modified Albumin (IMA) and Others), Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis and Others) and Region.



On the basis of geography, the market of Cardiac Biomarkers Testing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. If we see Market by Product, the sub-segment i.e. Instruments will boost the Cardiac Biomarkers Testing market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Location of Testing, the sub-segment i.e. Point of Care Testing will boost the Cardiac Biomarkers Testing market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Surging Preference for Point of Care (POC) Cardiac Testing Kits, Increase in R&D Activities related to Cardiac Biomarkers and Point-of-care Testing (POCT) with cardiac biomarkers

Market Growth Drivers:
Increasing Prevalence of Cardiovascular Diseases and Rising Technological Advancements using Cardiac Biomarkers Combinations

Challenges:
Streight Government Regulation

Restraints:
Confirmation in Result and Complex Process

Opportunities:
Increase in Awareness about the Importance of Early Diagnosis and Advancements in Healthcare Facilities

Market Leaders and their expansionary development strategies
In October 2023, Global medical devices and solutions provider Mindray has announced the introduction and global launch of two new high-sensitivity troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers. The additions enhance Mindray's diverse portfolio of cardiac biomarkers for diagnosing and managing cardiovascular diseases (CVDs), according to a written statement issued recently on the launch
In April 2021, Roche announced the series of five intended uses for two key cardiac biomarkers using Elecsys technology and In April 2021, Siemens AG announced that they received CE Mark approval for the point of care Atellica VLTiPatient side immunoassay Analyzer


Key Target Audience
Cardiac Biomarkers Testing Providers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Myocardial Muscle Creatine Kinase (CK-MB)
  • Troponins (T and I)
  • Myoglobin
  • Brain Natriuretic Peptide (BNPs) or NT-proBNP
  • Ischemia-modified Albumin (IMA)
  • Others
By Application
  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome
  • Atherosclerosis
  • Others
By Product
  • Instruments
  • Chemiluminescence
  • Immunofluorescence
  • ELISA
  • Immunochromatography
  • Reagents and Kits

By Location of Testing
  • Point of Care Testing
  • Laboratory Testing

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Cardiovascular Diseases
      • 3.2.2. Rising Technological Advancements using Cardiac Biomarkers Combinations
    • 3.3. Market Challenges
      • 3.3.1. Streight Government Regulation
    • 3.4. Market Trends
      • 3.4.1. Surging Preference for Point of Care (POC) Cardiac Testing Kits
      • 3.4.2. Increase in R&D Activities related to Cardiac Biomarkers
      • 3.4.3. Point-of-care Testing (POCT) with cardiac biomarkers
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cardiac Biomarkers Testing, by Type, Application, Product, Location of Testing and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Cardiac Biomarkers Testing (Value)
      • 5.2.1. Global Cardiac Biomarkers Testing by: Type (Value)
        • 5.2.1.1. Myocardial Muscle Creatine Kinase (CK-MB)
        • 5.2.1.2. Troponins (T and I)
        • 5.2.1.3. Myoglobin
        • 5.2.1.4. Brain Natriuretic Peptide (BNPs) or NT-proBNP
        • 5.2.1.5. Ischemia-modified Albumin (IMA)
        • 5.2.1.6. Others
      • 5.2.2. Global Cardiac Biomarkers Testing by: Application (Value)
        • 5.2.2.1. Myocardial Infarction
        • 5.2.2.2. Congestive Heart Failure
        • 5.2.2.3. Acute Coronary Syndrome
        • 5.2.2.4. Atherosclerosis
        • 5.2.2.5. Others
      • 5.2.3. Global Cardiac Biomarkers Testing by: Product (Value)
        • 5.2.3.1. Instruments
        • 5.2.3.2. Chemiluminescence
        • 5.2.3.3. Immunofluorescence
        • 5.2.3.4. ELISA
        • 5.2.3.5. Immunochromatography
        • 5.2.3.6. Reagents and Kits
      • 5.2.4. Global Cardiac Biomarkers Testing by: Location of Testing (Value)
        • 5.2.4.1. Point of Care Testing
        • 5.2.4.2. Laboratory Testing
      • 5.2.5. Global Cardiac Biomarkers Testing Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Cardiac Biomarkers Testing (Price)
      • 5.3.1. Global Cardiac Biomarkers Testing by: Type (Price)
  • 6. Cardiac Biomarkers Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Becton, Dickinson and Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. BioMerieux SA (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bio-Rad Laboratories, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Danaher Corporation (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Roche Holding AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Siemens AG (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Thermo Fisher Scientific, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Cardiac Biomarkers Testing Sale, by Type, Application, Product, Location of Testing and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Cardiac Biomarkers Testing (Value)
      • 7.2.1. Global Cardiac Biomarkers Testing by: Type (Value)
        • 7.2.1.1. Myocardial Muscle Creatine Kinase (CK-MB)
        • 7.2.1.2. Troponins (T and I)
        • 7.2.1.3. Myoglobin
        • 7.2.1.4. Brain Natriuretic Peptide (BNPs) or NT-proBNP
        • 7.2.1.5. Ischemia-modified Albumin (IMA)
        • 7.2.1.6. Others
      • 7.2.2. Global Cardiac Biomarkers Testing by: Application (Value)
        • 7.2.2.1. Myocardial Infarction
        • 7.2.2.2. Congestive Heart Failure
        • 7.2.2.3. Acute Coronary Syndrome
        • 7.2.2.4. Atherosclerosis
        • 7.2.2.5. Others
      • 7.2.3. Global Cardiac Biomarkers Testing by: Product (Value)
        • 7.2.3.1. Instruments
        • 7.2.3.2. Chemiluminescence
        • 7.2.3.3. Immunofluorescence
        • 7.2.3.4. ELISA
        • 7.2.3.5. Immunochromatography
        • 7.2.3.6. Reagents and Kits
      • 7.2.4. Global Cardiac Biomarkers Testing by: Location of Testing (Value)
        • 7.2.4.1. Point of Care Testing
        • 7.2.4.2. Laboratory Testing
      • 7.2.5. Global Cardiac Biomarkers Testing Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Cardiac Biomarkers Testing (Price)
      • 7.3.1. Global Cardiac Biomarkers Testing by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cardiac Biomarkers Testing: by Type(USD Billion)
  • Table 2. Cardiac Biomarkers Testing Myocardial Muscle Creatine Kinase (CK-MB) , by Region USD Billion (2018-2023)
  • Table 3. Cardiac Biomarkers Testing Troponins (T and I) , by Region USD Billion (2018-2023)
  • Table 4. Cardiac Biomarkers Testing Myoglobin , by Region USD Billion (2018-2023)
  • Table 5. Cardiac Biomarkers Testing Brain Natriuretic Peptide (BNPs) or NT-proBNP , by Region USD Billion (2018-2023)
  • Table 6. Cardiac Biomarkers Testing Ischemia-modified Albumin (IMA) , by Region USD Billion (2018-2023)
  • Table 7. Cardiac Biomarkers Testing Others , by Region USD Billion (2018-2023)
  • Table 8. Cardiac Biomarkers Testing: by Application(USD Billion)
  • Table 9. Cardiac Biomarkers Testing Myocardial Infarction , by Region USD Billion (2018-2023)
  • Table 10. Cardiac Biomarkers Testing Congestive Heart Failure , by Region USD Billion (2018-2023)
  • Table 11. Cardiac Biomarkers Testing Acute Coronary Syndrome , by Region USD Billion (2018-2023)
  • Table 12. Cardiac Biomarkers Testing Atherosclerosis , by Region USD Billion (2018-2023)
  • Table 13. Cardiac Biomarkers Testing Others , by Region USD Billion (2018-2023)
  • Table 14. Cardiac Biomarkers Testing: by Product(USD Billion)
  • Table 15. Cardiac Biomarkers Testing Instruments , by Region USD Billion (2018-2023)
  • Table 16. Cardiac Biomarkers Testing Chemiluminescence , by Region USD Billion (2018-2023)
  • Table 17. Cardiac Biomarkers Testing Immunofluorescence , by Region USD Billion (2018-2023)
  • Table 18. Cardiac Biomarkers Testing ELISA , by Region USD Billion (2018-2023)
  • Table 19. Cardiac Biomarkers Testing Immunochromatography , by Region USD Billion (2018-2023)
  • Table 20. Cardiac Biomarkers Testing Reagents and Kits , by Region USD Billion (2018-2023)
  • Table 21. Cardiac Biomarkers Testing: by Location of Testing(USD Billion)
  • Table 22. Cardiac Biomarkers Testing Point of Care Testing , by Region USD Billion (2018-2023)
  • Table 23. Cardiac Biomarkers Testing Laboratory Testing , by Region USD Billion (2018-2023)
  • Table 24. South America Cardiac Biomarkers Testing, by Country USD Billion (2018-2023)
  • Table 25. South America Cardiac Biomarkers Testing, by Type USD Billion (2018-2023)
  • Table 26. South America Cardiac Biomarkers Testing, by Application USD Billion (2018-2023)
  • Table 27. South America Cardiac Biomarkers Testing, by Product USD Billion (2018-2023)
  • Table 28. South America Cardiac Biomarkers Testing, by Location of Testing USD Billion (2018-2023)
  • Table 29. Brazil Cardiac Biomarkers Testing, by Type USD Billion (2018-2023)
  • Table 30. Brazil Cardiac Biomarkers Testing, by Application USD Billion (2018-2023)
  • Table 31. Brazil Cardiac Biomarkers Testing, by Product USD Billion (2018-2023)
  • Table 32. Brazil Cardiac Biomarkers Testing, by Location of Testing USD Billion (2018-2023)
  • Table 33. Argentina Cardiac Biomarkers Testing, by Type USD Billion (2018-2023)
  • Table 34. Argentina Cardiac Biomarkers Testing, by Application USD Billion (2018-2023)
  • Table 35. Argentina Cardiac Biomarkers Testing, by Product USD Billion (2018-2023)
  • Table 36. Argentina Cardiac Biomarkers Testing, by Location of Testing USD Billion (2018-2023)
  • Table 37. Rest of South America Cardiac Biomarkers Testing, by Type USD Billion (2018-2023)
  • Table 38. Rest of South America Cardiac Biomarkers Testing, by Application USD Billion (2018-2023)
  • Table 39. Rest of South America Cardiac Biomarkers Testing, by Product USD Billion (2018-2023)
  • Table 40. Rest of South America Cardiac Biomarkers Testing, by Location of Testing USD Billion (2018-2023)
  • Table 41. Asia Pacific Cardiac Biomarkers Testing, by Country USD Billion (2018-2023)
  • Table 42. Asia Pacific Cardiac Biomarkers Testing, by Type USD Billion (2018-2023)
  • Table 43. Asia Pacific Cardiac Biomarkers Testing, by Application USD Billion (2018-2023)
  • Table 44. Asia Pacific Cardiac Biomarkers Testing, by Product USD Billion (2018-2023)
  • Table 45. Asia Pacific Cardiac Biomarkers Testing, by Location of Testing USD Billion (2018-2023)
  • Table 46. China Cardiac Biomarkers Testing, by Type USD Billion (2018-2023)
  • Table 47. China Cardiac Biomarkers Testing, by Application USD Billion (2018-2023)
  • Table 48. China Cardiac Biomarkers Testing, by Product USD Billion (2018-2023)
  • Table 49. China Cardiac Biomarkers Testing, by Location of Testing USD Billion (2018-2023)
  • Table 50. Japan Cardiac Biomarkers Testing, by Type USD Billion (2018-2023)
  • Table 51. Japan Cardiac Biomarkers Testing, by Application USD Billion (2018-2023)
  • Table 52. Japan Cardiac Biomarkers Testing, by Product USD Billion (2018-2023)
  • Table 53. Japan Cardiac Biomarkers Testing, by Location of Testing USD Billion (2018-2023)
  • Table 54. India Cardiac Biomarkers Testing, by Type USD Billion (2018-2023)
  • Table 55. India Cardiac Biomarkers Testing, by Application USD Billion (2018-2023)
  • Table 56. India Cardiac Biomarkers Testing, by Product USD Billion (2018-2023)
  • Table 57. India Cardiac Biomarkers Testing, by Location of Testing USD Billion (2018-2023)
  • Table 58. South Korea Cardiac Biomarkers Testing, by Type USD Billion (2018-2023)
  • Table 59. South Korea Cardiac Biomarkers Testing, by Application USD Billion (2018-2023)
  • Table 60. South Korea Cardiac Biomarkers Testing, by Product USD Billion (2018-2023)
  • Table 61. South Korea Cardiac Biomarkers Testing, by Location of Testing USD Billion (2018-2023)
  • Table 62. Taiwan Cardiac Biomarkers Testing, by Type USD Billion (2018-2023)
  • Table 63. Taiwan Cardiac Biomarkers Testing, by Application USD Billion (2018-2023)
  • Table 64. Taiwan Cardiac Biomarkers Testing, by Product USD Billion (2018-2023)
  • Table 65. Taiwan Cardiac Biomarkers Testing, by Location of Testing USD Billion (2018-2023)
  • Table 66. Australia Cardiac Biomarkers Testing, by Type USD Billion (2018-2023)
  • Table 67. Australia Cardiac Biomarkers Testing, by Application USD Billion (2018-2023)
  • Table 68. Australia Cardiac Biomarkers Testing, by Product USD Billion (2018-2023)
  • Table 69. Australia Cardiac Biomarkers Testing, by Location of Testing USD Billion (2018-2023)
  • Table 70. Rest of Asia-Pacific Cardiac Biomarkers Testing, by Type USD Billion (2018-2023)
  • Table 71. Rest of Asia-Pacific Cardiac Biomarkers Testing, by Application USD Billion (2018-2023)
  • Table 72. Rest of Asia-Pacific Cardiac Biomarkers Testing, by Product USD Billion (2018-2023)
  • Table 73. Rest of Asia-Pacific Cardiac Biomarkers Testing, by Location of Testing USD Billion (2018-2023)
  • Table 74. Europe Cardiac Biomarkers Testing, by Country USD Billion (2018-2023)
  • Table 75. Europe Cardiac Biomarkers Testing, by Type USD Billion (2018-2023)
  • Table 76. Europe Cardiac Biomarkers Testing, by Application USD Billion (2018-2023)
  • Table 77. Europe Cardiac Biomarkers Testing, by Product USD Billion (2018-2023)
  • Table 78. Europe Cardiac Biomarkers Testing, by Location of Testing USD Billion (2018-2023)
  • Table 79. Germany Cardiac Biomarkers Testing, by Type USD Billion (2018-2023)
  • Table 80. Germany Cardiac Biomarkers Testing, by Application USD Billion (2018-2023)
  • Table 81. Germany Cardiac Biomarkers Testing, by Product USD Billion (2018-2023)
  • Table 82. Germany Cardiac Biomarkers Testing, by Location of Testing USD Billion (2018-2023)
  • Table 83. France Cardiac Biomarkers Testing, by Type USD Billion (2018-2023)
  • Table 84. France Cardiac Biomarkers Testing, by Application USD Billion (2018-2023)
  • Table 85. France Cardiac Biomarkers Testing, by Product USD Billion (2018-2023)
  • Table 86. France Cardiac Biomarkers Testing, by Location of Testing USD Billion (2018-2023)
  • Table 87. Italy Cardiac Biomarkers Testing, by Type USD Billion (2018-2023)
  • Table 88. Italy Cardiac Biomarkers Testing, by Application USD Billion (2018-2023)
  • Table 89. Italy Cardiac Biomarkers Testing, by Product USD Billion (2018-2023)
  • Table 90. Italy Cardiac Biomarkers Testing, by Location of Testing USD Billion (2018-2023)
  • Table 91. United Kingdom Cardiac Biomarkers Testing, by Type USD Billion (2018-2023)
  • Table 92. United Kingdom Cardiac Biomarkers Testing, by Application USD Billion (2018-2023)
  • Table 93. United Kingdom Cardiac Biomarkers Testing, by Product USD Billion (2018-2023)
  • Table 94. United Kingdom Cardiac Biomarkers Testing, by Location of Testing USD Billion (2018-2023)
  • Table 95. Netherlands Cardiac Biomarkers Testing, by Type USD Billion (2018-2023)
  • Table 96. Netherlands Cardiac Biomarkers Testing, by Application USD Billion (2018-2023)
  • Table 97. Netherlands Cardiac Biomarkers Testing, by Product USD Billion (2018-2023)
  • Table 98. Netherlands Cardiac Biomarkers Testing, by Location of Testing USD Billion (2018-2023)
  • Table 99. Rest of Europe Cardiac Biomarkers Testing, by Type USD Billion (2018-2023)
  • Table 100. Rest of Europe Cardiac Biomarkers Testing, by Application USD Billion (2018-2023)
  • Table 101. Rest of Europe Cardiac Biomarkers Testing, by Product USD Billion (2018-2023)
  • Table 102. Rest of Europe Cardiac Biomarkers Testing, by Location of Testing USD Billion (2018-2023)
  • Table 103. MEA Cardiac Biomarkers Testing, by Country USD Billion (2018-2023)
  • Table 104. MEA Cardiac Biomarkers Testing, by Type USD Billion (2018-2023)
  • Table 105. MEA Cardiac Biomarkers Testing, by Application USD Billion (2018-2023)
  • Table 106. MEA Cardiac Biomarkers Testing, by Product USD Billion (2018-2023)
  • Table 107. MEA Cardiac Biomarkers Testing, by Location of Testing USD Billion (2018-2023)
  • Table 108. Middle East Cardiac Biomarkers Testing, by Type USD Billion (2018-2023)
  • Table 109. Middle East Cardiac Biomarkers Testing, by Application USD Billion (2018-2023)
  • Table 110. Middle East Cardiac Biomarkers Testing, by Product USD Billion (2018-2023)
  • Table 111. Middle East Cardiac Biomarkers Testing, by Location of Testing USD Billion (2018-2023)
  • Table 112. Africa Cardiac Biomarkers Testing, by Type USD Billion (2018-2023)
  • Table 113. Africa Cardiac Biomarkers Testing, by Application USD Billion (2018-2023)
  • Table 114. Africa Cardiac Biomarkers Testing, by Product USD Billion (2018-2023)
  • Table 115. Africa Cardiac Biomarkers Testing, by Location of Testing USD Billion (2018-2023)
  • Table 116. North America Cardiac Biomarkers Testing, by Country USD Billion (2018-2023)
  • Table 117. North America Cardiac Biomarkers Testing, by Type USD Billion (2018-2023)
  • Table 118. North America Cardiac Biomarkers Testing, by Application USD Billion (2018-2023)
  • Table 119. North America Cardiac Biomarkers Testing, by Product USD Billion (2018-2023)
  • Table 120. North America Cardiac Biomarkers Testing, by Location of Testing USD Billion (2018-2023)
  • Table 121. United States Cardiac Biomarkers Testing, by Type USD Billion (2018-2023)
  • Table 122. United States Cardiac Biomarkers Testing, by Application USD Billion (2018-2023)
  • Table 123. United States Cardiac Biomarkers Testing, by Product USD Billion (2018-2023)
  • Table 124. United States Cardiac Biomarkers Testing, by Location of Testing USD Billion (2018-2023)
  • Table 125. Canada Cardiac Biomarkers Testing, by Type USD Billion (2018-2023)
  • Table 126. Canada Cardiac Biomarkers Testing, by Application USD Billion (2018-2023)
  • Table 127. Canada Cardiac Biomarkers Testing, by Product USD Billion (2018-2023)
  • Table 128. Canada Cardiac Biomarkers Testing, by Location of Testing USD Billion (2018-2023)
  • Table 129. Mexico Cardiac Biomarkers Testing, by Type USD Billion (2018-2023)
  • Table 130. Mexico Cardiac Biomarkers Testing, by Application USD Billion (2018-2023)
  • Table 131. Mexico Cardiac Biomarkers Testing, by Product USD Billion (2018-2023)
  • Table 132. Mexico Cardiac Biomarkers Testing, by Location of Testing USD Billion (2018-2023)
  • Table 133. Cardiac Biomarkers Testing: by Type(USD/Units)
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Cardiac Biomarkers Testing: by Type(USD Billion)
  • Table 143. Cardiac Biomarkers Testing Myocardial Muscle Creatine Kinase (CK-MB) , by Region USD Billion (2025-2030)
  • Table 144. Cardiac Biomarkers Testing Troponins (T and I) , by Region USD Billion (2025-2030)
  • Table 145. Cardiac Biomarkers Testing Myoglobin , by Region USD Billion (2025-2030)
  • Table 146. Cardiac Biomarkers Testing Brain Natriuretic Peptide (BNPs) or NT-proBNP , by Region USD Billion (2025-2030)
  • Table 147. Cardiac Biomarkers Testing Ischemia-modified Albumin (IMA) , by Region USD Billion (2025-2030)
  • Table 148. Cardiac Biomarkers Testing Others , by Region USD Billion (2025-2030)
  • Table 149. Cardiac Biomarkers Testing: by Application(USD Billion)
  • Table 150. Cardiac Biomarkers Testing Myocardial Infarction , by Region USD Billion (2025-2030)
  • Table 151. Cardiac Biomarkers Testing Congestive Heart Failure , by Region USD Billion (2025-2030)
  • Table 152. Cardiac Biomarkers Testing Acute Coronary Syndrome , by Region USD Billion (2025-2030)
  • Table 153. Cardiac Biomarkers Testing Atherosclerosis , by Region USD Billion (2025-2030)
  • Table 154. Cardiac Biomarkers Testing Others , by Region USD Billion (2025-2030)
  • Table 155. Cardiac Biomarkers Testing: by Product(USD Billion)
  • Table 156. Cardiac Biomarkers Testing Instruments , by Region USD Billion (2025-2030)
  • Table 157. Cardiac Biomarkers Testing Chemiluminescence , by Region USD Billion (2025-2030)
  • Table 158. Cardiac Biomarkers Testing Immunofluorescence , by Region USD Billion (2025-2030)
  • Table 159. Cardiac Biomarkers Testing ELISA , by Region USD Billion (2025-2030)
  • Table 160. Cardiac Biomarkers Testing Immunochromatography , by Region USD Billion (2025-2030)
  • Table 161. Cardiac Biomarkers Testing Reagents and Kits , by Region USD Billion (2025-2030)
  • Table 162. Cardiac Biomarkers Testing: by Location of Testing(USD Billion)
  • Table 163. Cardiac Biomarkers Testing Point of Care Testing , by Region USD Billion (2025-2030)
  • Table 164. Cardiac Biomarkers Testing Laboratory Testing , by Region USD Billion (2025-2030)
  • Table 165. South America Cardiac Biomarkers Testing, by Country USD Billion (2025-2030)
  • Table 166. South America Cardiac Biomarkers Testing, by Type USD Billion (2025-2030)
  • Table 167. South America Cardiac Biomarkers Testing, by Application USD Billion (2025-2030)
  • Table 168. South America Cardiac Biomarkers Testing, by Product USD Billion (2025-2030)
  • Table 169. South America Cardiac Biomarkers Testing, by Location of Testing USD Billion (2025-2030)
  • Table 170. Brazil Cardiac Biomarkers Testing, by Type USD Billion (2025-2030)
  • Table 171. Brazil Cardiac Biomarkers Testing, by Application USD Billion (2025-2030)
  • Table 172. Brazil Cardiac Biomarkers Testing, by Product USD Billion (2025-2030)
  • Table 173. Brazil Cardiac Biomarkers Testing, by Location of Testing USD Billion (2025-2030)
  • Table 174. Argentina Cardiac Biomarkers Testing, by Type USD Billion (2025-2030)
  • Table 175. Argentina Cardiac Biomarkers Testing, by Application USD Billion (2025-2030)
  • Table 176. Argentina Cardiac Biomarkers Testing, by Product USD Billion (2025-2030)
  • Table 177. Argentina Cardiac Biomarkers Testing, by Location of Testing USD Billion (2025-2030)
  • Table 178. Rest of South America Cardiac Biomarkers Testing, by Type USD Billion (2025-2030)
  • Table 179. Rest of South America Cardiac Biomarkers Testing, by Application USD Billion (2025-2030)
  • Table 180. Rest of South America Cardiac Biomarkers Testing, by Product USD Billion (2025-2030)
  • Table 181. Rest of South America Cardiac Biomarkers Testing, by Location of Testing USD Billion (2025-2030)
  • Table 182. Asia Pacific Cardiac Biomarkers Testing, by Country USD Billion (2025-2030)
  • Table 183. Asia Pacific Cardiac Biomarkers Testing, by Type USD Billion (2025-2030)
  • Table 184. Asia Pacific Cardiac Biomarkers Testing, by Application USD Billion (2025-2030)
  • Table 185. Asia Pacific Cardiac Biomarkers Testing, by Product USD Billion (2025-2030)
  • Table 186. Asia Pacific Cardiac Biomarkers Testing, by Location of Testing USD Billion (2025-2030)
  • Table 187. China Cardiac Biomarkers Testing, by Type USD Billion (2025-2030)
  • Table 188. China Cardiac Biomarkers Testing, by Application USD Billion (2025-2030)
  • Table 189. China Cardiac Biomarkers Testing, by Product USD Billion (2025-2030)
  • Table 190. China Cardiac Biomarkers Testing, by Location of Testing USD Billion (2025-2030)
  • Table 191. Japan Cardiac Biomarkers Testing, by Type USD Billion (2025-2030)
  • Table 192. Japan Cardiac Biomarkers Testing, by Application USD Billion (2025-2030)
  • Table 193. Japan Cardiac Biomarkers Testing, by Product USD Billion (2025-2030)
  • Table 194. Japan Cardiac Biomarkers Testing, by Location of Testing USD Billion (2025-2030)
  • Table 195. India Cardiac Biomarkers Testing, by Type USD Billion (2025-2030)
  • Table 196. India Cardiac Biomarkers Testing, by Application USD Billion (2025-2030)
  • Table 197. India Cardiac Biomarkers Testing, by Product USD Billion (2025-2030)
  • Table 198. India Cardiac Biomarkers Testing, by Location of Testing USD Billion (2025-2030)
  • Table 199. South Korea Cardiac Biomarkers Testing, by Type USD Billion (2025-2030)
  • Table 200. South Korea Cardiac Biomarkers Testing, by Application USD Billion (2025-2030)
  • Table 201. South Korea Cardiac Biomarkers Testing, by Product USD Billion (2025-2030)
  • Table 202. South Korea Cardiac Biomarkers Testing, by Location of Testing USD Billion (2025-2030)
  • Table 203. Taiwan Cardiac Biomarkers Testing, by Type USD Billion (2025-2030)
  • Table 204. Taiwan Cardiac Biomarkers Testing, by Application USD Billion (2025-2030)
  • Table 205. Taiwan Cardiac Biomarkers Testing, by Product USD Billion (2025-2030)
  • Table 206. Taiwan Cardiac Biomarkers Testing, by Location of Testing USD Billion (2025-2030)
  • Table 207. Australia Cardiac Biomarkers Testing, by Type USD Billion (2025-2030)
  • Table 208. Australia Cardiac Biomarkers Testing, by Application USD Billion (2025-2030)
  • Table 209. Australia Cardiac Biomarkers Testing, by Product USD Billion (2025-2030)
  • Table 210. Australia Cardiac Biomarkers Testing, by Location of Testing USD Billion (2025-2030)
  • Table 211. Rest of Asia-Pacific Cardiac Biomarkers Testing, by Type USD Billion (2025-2030)
  • Table 212. Rest of Asia-Pacific Cardiac Biomarkers Testing, by Application USD Billion (2025-2030)
  • Table 213. Rest of Asia-Pacific Cardiac Biomarkers Testing, by Product USD Billion (2025-2030)
  • Table 214. Rest of Asia-Pacific Cardiac Biomarkers Testing, by Location of Testing USD Billion (2025-2030)
  • Table 215. Europe Cardiac Biomarkers Testing, by Country USD Billion (2025-2030)
  • Table 216. Europe Cardiac Biomarkers Testing, by Type USD Billion (2025-2030)
  • Table 217. Europe Cardiac Biomarkers Testing, by Application USD Billion (2025-2030)
  • Table 218. Europe Cardiac Biomarkers Testing, by Product USD Billion (2025-2030)
  • Table 219. Europe Cardiac Biomarkers Testing, by Location of Testing USD Billion (2025-2030)
  • Table 220. Germany Cardiac Biomarkers Testing, by Type USD Billion (2025-2030)
  • Table 221. Germany Cardiac Biomarkers Testing, by Application USD Billion (2025-2030)
  • Table 222. Germany Cardiac Biomarkers Testing, by Product USD Billion (2025-2030)
  • Table 223. Germany Cardiac Biomarkers Testing, by Location of Testing USD Billion (2025-2030)
  • Table 224. France Cardiac Biomarkers Testing, by Type USD Billion (2025-2030)
  • Table 225. France Cardiac Biomarkers Testing, by Application USD Billion (2025-2030)
  • Table 226. France Cardiac Biomarkers Testing, by Product USD Billion (2025-2030)
  • Table 227. France Cardiac Biomarkers Testing, by Location of Testing USD Billion (2025-2030)
  • Table 228. Italy Cardiac Biomarkers Testing, by Type USD Billion (2025-2030)
  • Table 229. Italy Cardiac Biomarkers Testing, by Application USD Billion (2025-2030)
  • Table 230. Italy Cardiac Biomarkers Testing, by Product USD Billion (2025-2030)
  • Table 231. Italy Cardiac Biomarkers Testing, by Location of Testing USD Billion (2025-2030)
  • Table 232. United Kingdom Cardiac Biomarkers Testing, by Type USD Billion (2025-2030)
  • Table 233. United Kingdom Cardiac Biomarkers Testing, by Application USD Billion (2025-2030)
  • Table 234. United Kingdom Cardiac Biomarkers Testing, by Product USD Billion (2025-2030)
  • Table 235. United Kingdom Cardiac Biomarkers Testing, by Location of Testing USD Billion (2025-2030)
  • Table 236. Netherlands Cardiac Biomarkers Testing, by Type USD Billion (2025-2030)
  • Table 237. Netherlands Cardiac Biomarkers Testing, by Application USD Billion (2025-2030)
  • Table 238. Netherlands Cardiac Biomarkers Testing, by Product USD Billion (2025-2030)
  • Table 239. Netherlands Cardiac Biomarkers Testing, by Location of Testing USD Billion (2025-2030)
  • Table 240. Rest of Europe Cardiac Biomarkers Testing, by Type USD Billion (2025-2030)
  • Table 241. Rest of Europe Cardiac Biomarkers Testing, by Application USD Billion (2025-2030)
  • Table 242. Rest of Europe Cardiac Biomarkers Testing, by Product USD Billion (2025-2030)
  • Table 243. Rest of Europe Cardiac Biomarkers Testing, by Location of Testing USD Billion (2025-2030)
  • Table 244. MEA Cardiac Biomarkers Testing, by Country USD Billion (2025-2030)
  • Table 245. MEA Cardiac Biomarkers Testing, by Type USD Billion (2025-2030)
  • Table 246. MEA Cardiac Biomarkers Testing, by Application USD Billion (2025-2030)
  • Table 247. MEA Cardiac Biomarkers Testing, by Product USD Billion (2025-2030)
  • Table 248. MEA Cardiac Biomarkers Testing, by Location of Testing USD Billion (2025-2030)
  • Table 249. Middle East Cardiac Biomarkers Testing, by Type USD Billion (2025-2030)
  • Table 250. Middle East Cardiac Biomarkers Testing, by Application USD Billion (2025-2030)
  • Table 251. Middle East Cardiac Biomarkers Testing, by Product USD Billion (2025-2030)
  • Table 252. Middle East Cardiac Biomarkers Testing, by Location of Testing USD Billion (2025-2030)
  • Table 253. Africa Cardiac Biomarkers Testing, by Type USD Billion (2025-2030)
  • Table 254. Africa Cardiac Biomarkers Testing, by Application USD Billion (2025-2030)
  • Table 255. Africa Cardiac Biomarkers Testing, by Product USD Billion (2025-2030)
  • Table 256. Africa Cardiac Biomarkers Testing, by Location of Testing USD Billion (2025-2030)
  • Table 257. North America Cardiac Biomarkers Testing, by Country USD Billion (2025-2030)
  • Table 258. North America Cardiac Biomarkers Testing, by Type USD Billion (2025-2030)
  • Table 259. North America Cardiac Biomarkers Testing, by Application USD Billion (2025-2030)
  • Table 260. North America Cardiac Biomarkers Testing, by Product USD Billion (2025-2030)
  • Table 261. North America Cardiac Biomarkers Testing, by Location of Testing USD Billion (2025-2030)
  • Table 262. United States Cardiac Biomarkers Testing, by Type USD Billion (2025-2030)
  • Table 263. United States Cardiac Biomarkers Testing, by Application USD Billion (2025-2030)
  • Table 264. United States Cardiac Biomarkers Testing, by Product USD Billion (2025-2030)
  • Table 265. United States Cardiac Biomarkers Testing, by Location of Testing USD Billion (2025-2030)
  • Table 266. Canada Cardiac Biomarkers Testing, by Type USD Billion (2025-2030)
  • Table 267. Canada Cardiac Biomarkers Testing, by Application USD Billion (2025-2030)
  • Table 268. Canada Cardiac Biomarkers Testing, by Product USD Billion (2025-2030)
  • Table 269. Canada Cardiac Biomarkers Testing, by Location of Testing USD Billion (2025-2030)
  • Table 270. Mexico Cardiac Biomarkers Testing, by Type USD Billion (2025-2030)
  • Table 271. Mexico Cardiac Biomarkers Testing, by Application USD Billion (2025-2030)
  • Table 272. Mexico Cardiac Biomarkers Testing, by Product USD Billion (2025-2030)
  • Table 273. Mexico Cardiac Biomarkers Testing, by Location of Testing USD Billion (2025-2030)
  • Table 274. Cardiac Biomarkers Testing: by Type(USD/Units)
  • Table 275. Research Programs/Design for This Report
  • Table 276. Key Data Information from Secondary Sources
  • Table 277. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cardiac Biomarkers Testing: by Type USD Billion (2018-2023)
  • Figure 5. Global Cardiac Biomarkers Testing: by Application USD Billion (2018-2023)
  • Figure 6. Global Cardiac Biomarkers Testing: by Product USD Billion (2018-2023)
  • Figure 7. Global Cardiac Biomarkers Testing: by Location of Testing USD Billion (2018-2023)
  • Figure 8. South America Cardiac Biomarkers Testing Share (%), by Country
  • Figure 9. Asia Pacific Cardiac Biomarkers Testing Share (%), by Country
  • Figure 10. Europe Cardiac Biomarkers Testing Share (%), by Country
  • Figure 11. MEA Cardiac Biomarkers Testing Share (%), by Country
  • Figure 12. North America Cardiac Biomarkers Testing Share (%), by Country
  • Figure 13. Global Cardiac Biomarkers Testing: by Type USD/Units (2018-2023)
  • Figure 14. Global Cardiac Biomarkers Testing share by Players 2023 (%)
  • Figure 15. Global Cardiac Biomarkers Testing share by Players (Top 3) 2023(%)
  • Figure 16. Global Cardiac Biomarkers Testing share by Players (Top 5) 2023(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 19. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 20. Becton, Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 21. Becton, Dickinson and Company (United States) Revenue: by Geography 2023
  • Figure 22. BioMerieux SA (France) Revenue, Net Income and Gross profit
  • Figure 23. BioMerieux SA (France) Revenue: by Geography 2023
  • Figure 24. Bio-Rad Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Bio-Rad Laboratories, Inc. (United States) Revenue: by Geography 2023
  • Figure 26. Danaher Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 27. Danaher Corporation (United States) Revenue: by Geography 2023
  • Figure 28. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. Roche Holding AG (Switzerland) Revenue: by Geography 2023
  • Figure 30. Siemens AG (Germany) Revenue, Net Income and Gross profit
  • Figure 31. Siemens AG (Germany) Revenue: by Geography 2023
  • Figure 32. Thermo Fisher Scientific, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Thermo Fisher Scientific, Inc. (United States) Revenue: by Geography 2023
  • Figure 34. Global Cardiac Biomarkers Testing: by Type USD Billion (2025-2030)
  • Figure 35. Global Cardiac Biomarkers Testing: by Application USD Billion (2025-2030)
  • Figure 36. Global Cardiac Biomarkers Testing: by Product USD Billion (2025-2030)
  • Figure 37. Global Cardiac Biomarkers Testing: by Location of Testing USD Billion (2025-2030)
  • Figure 38. South America Cardiac Biomarkers Testing Share (%), by Country
  • Figure 39. Asia Pacific Cardiac Biomarkers Testing Share (%), by Country
  • Figure 40. Europe Cardiac Biomarkers Testing Share (%), by Country
  • Figure 41. MEA Cardiac Biomarkers Testing Share (%), by Country
  • Figure 42. North America Cardiac Biomarkers Testing Share (%), by Country
  • Figure 43. Global Cardiac Biomarkers Testing: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories (United States)
  • Becton, Dickinson and Company (United States)
  • BioMerieux SA (France)
  • Bio-Rad Laboratories, Inc. (United States)
  • Danaher Corporation (United States)
  • Roche Holding AG (Switzerland)
  • Siemens AG (Germany)
  • Thermo Fisher Scientific, Inc. (United States)
Additional players considered in the study are as follows:
PerkinElmer Inc. (United kingdom) , Tosoh Corporation (Japan)
Select User Access Type

Key Highlights of Report


Mar 2024 178 Pages 71 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Cardiac Biomarkers Testing Market Quantitative research analysis
Global Cardiac Biomarkers Testing Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Abbott Laboratories (United States), Becton, Dickinson and Company (United States), BioMerieux SA (France), Bio-Rad Laboratories, Inc. (United States), Danaher Corporation (United States), Roche Holding AG (Switzerland), Siemens AG (Germany) and Thermo Fisher Scientific, Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Surging Preference for Point of Care (POC) Cardiac Testing Kits " is seen as one of major influencing trends for Cardiac Biomarkers Testing Market during projected period 2023-2030.
The Cardiac Biomarkers Testing market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Cardiac Biomarkers Testing Market Report?

Have a Query? Click Here

Other Related Reports

Rapid Tests Comprehensive Study by Type (Over-the-counter (OTC) Rapid Test Product, Professional Rapid Test Product), Application (Infectious Disease, Cardiology, Oncology, Pregnancy and Fertility, T...
$ 3750
Virtual Reality (VR) in Healthcare Comprehensive Study by Application (Surgical Training, Surgical Navigation, Others), Components (Software System, Hardware Devices, Services), End Users (Hospitals,...
$ 3750
Mobile Health Vehicle Comprehensive Study by Type (Van, Truck, Trailer, Others), Application (Intensive Care, Dental Care, Blood Donation, Medical Imaging, Others) Players and Region - Global Market ...
$ 3500
Healthcare Facility Management Comprehensive Study by Type (Plumbing, Air Conditioning Maintenance, Fire Protection Systems, Mechanical and Electrical Maintenance, Cleaning and Pest Control, Laundry/...
$ 3800
Wound Debridement Comprehensive Study by Type (Gels, Ointments, Surgical devices, Medical gauzes, Ultrasonic devices, Others), Type of Wound (Acute Wound (Incision Wounds, Abrasion Wounds, Others), C...
$ 3750
Bamboo Leaf Extract Comprehensive Study by Application (Cosmetic, Health care, Chemical, Food, Nutraceuticals, Others), Type (Powder, Liquid), Channel (Direct channel, Indirect channel, Other), Mode ...
$ 3650